NCT05133531: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 2 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05133531 |
|---|---|
| Title | A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 1, 2022 |
| Completion date | Jan. 28, 2027 |
| Required reporting date | Jan. 28, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |